Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an integral role in the degradation of low-density lipoprotein receptors (LDL-R), making it an intriguing target for emerging pharmacotherapy. Two PCSK9 inhibitors, alirocumab and evolocumab, have been approved and are available in the United States and European Union. However, much of the PCSK9 story remains to be told. The pipeline for additional pharmacotherapy options is rich with several compounds under development, using alternative strategies for inhibiting PCSK9. Perhaps, more intriguing is the interaction between PCSK9 and non-LDL-R targets, including mediators of inflammation and immunological processes, which remain under intense investigation. This review will discuss the currently available PCSK9 inhibitors, the development of novel approaches to PCSK9 modulation, and the potential non-LDLR-mediated effects of PCSK9 inhibition.

A review of PCSK9 inhibition and its effects beyond LDL receptors / Dixon, Dave L.; Trankle, Cory; Buckley, Leo; Parod, Eric; Carbone, Salvatore; Van Tassell, Benjamin W.; Abbate, Antonio. - In: JOURNAL OF CLINICAL LIPIDOLOGY. - ISSN 1933-2874. - 10:5(2016), pp. 1073-1080. [10.1016/j.jacl.2016.07.004]

A review of PCSK9 inhibition and its effects beyond LDL receptors

Carbone, Salvatore;Abbate, Antonio
2016

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an integral role in the degradation of low-density lipoprotein receptors (LDL-R), making it an intriguing target for emerging pharmacotherapy. Two PCSK9 inhibitors, alirocumab and evolocumab, have been approved and are available in the United States and European Union. However, much of the PCSK9 story remains to be told. The pipeline for additional pharmacotherapy options is rich with several compounds under development, using alternative strategies for inhibiting PCSK9. Perhaps, more intriguing is the interaction between PCSK9 and non-LDL-R targets, including mediators of inflammation and immunological processes, which remain under intense investigation. This review will discuss the currently available PCSK9 inhibitors, the development of novel approaches to PCSK9 modulation, and the potential non-LDLR-mediated effects of PCSK9 inhibition.
2016
alirocumab; dyslipidemia; evolocumab; PCSK9
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
A review of PCSK9 inhibition and its effects beyond LDL receptors / Dixon, Dave L.; Trankle, Cory; Buckley, Leo; Parod, Eric; Carbone, Salvatore; Van Tassell, Benjamin W.; Abbate, Antonio. - In: JOURNAL OF CLINICAL LIPIDOLOGY. - ISSN 1933-2874. - 10:5(2016), pp. 1073-1080. [10.1016/j.jacl.2016.07.004]
File allegati a questo prodotto
File Dimensione Formato  
Dixon_PCSK9_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 508.47 kB
Formato Adobe PDF
508.47 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1021223
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 41
social impact